close

Æterna Zentaris Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for endocrine therapy and oncology. Its lead product candidates include cetrorelix, a luteinizing hormone-releasing hormone (LHRH) antagonist that has completed Phase III trial for benign prostatic hyperplasia (BPH) indication; and AEZS-108, a Phase II clinical trial product for the treatment of advanced ovarian and endometrial cancers. The company also develops drugs, which are in Phase II clinical trials, including Cetrorelix for endometriosis in Japan; Ozarelix for the treatment of BPH and prostate cancer; and Perifosine for various cancers. Its products under Phase I clinical trials also comprise AEZS-112 for oncology; and AEZS-130 for endocrinology. In addition, the company's product pipeline comprises AEZS-115, an LHRH antagonist for endometriosis and urology; AEZS-120, a urology vaccine; AEZS-126 Erk and PI3K inhibitors for oncology; AEZS-127 ErPC for oncology; and Ghrelin receptor ligands for endocrinology. Further, it offers Cetrotide for the treatment of infertility. Æterna Zentaris has partnership agreements with Shionogi and Co.; sanofi-aventis; ARES Trading S.A.; Nippon Kayaku Co. Ltd.; Spectrum Pharmaceuticals, Inc.; Handok Pharmaceuticals Co., Ltd.; and Keryx Biopharmaceuticals, Inc. The company sells its products in the United States, Canada, Switzerland, the United Kingdom, the Netherlands, and Japan. Æterna Zentaris was founded in 1990 and is headquartered in Quebec, Canada.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	1.71
Volume	(mio) 1.31
Volume Avg	(mio) 1.28
52 Week High	2.68
52 Week Low	1.35
PE	N/A
PE (group average)	39
EPS Year	-0.23
EPS change Q/Q	-33.33%
EPS change Q/Q Yr ago	1000%
EPS change Q/Q next Q est	-14.29%
EPS change Y/Y	-7.89%
REV change Q/Q	75.44%
REV change Q/Q Yr ago	-75.12%
EPS next Q est	-0.07
EPS next Y est	-0.26
Divident Annual	0.00
Dividend Yield	0%